2-Year outcomes of dolutegravir plus lamivudine in ART-naive and pre-treated people living with HIV in Germany: Real-world Data From the URBAN Cohort

被引：0
|
作者：
Beer, Daniel [1 ]
Scherzer, Jenny [2 ]
Noe, Sebastian [3 ]
Scholten, Stefan [4 ]
Wyen, Christoph [5 ]
Postel, Nils [6 ]
Degen, Olaf [7 ]
Sabranski, Michael [8 ]
Westermayer, Bernd [9 ]
Dymek, Kathrin M. [2 ]
Baum, Alexander [2 ]
机构：
[1] IPZB Aachen Praxis Dr H Knechten, Aachen, Germany
[2] ViiV Healthcare, Munich, Germany
[3] MVZ Munchen Goethepl, Munich, Germany
[4] Praxis Hohenstaufenring, Cologne, Germany
[5] Praxis Ebertpl, Cologne, Germany
[6] Prinzmed, Munich, Germany
[7] Univ Klinikum Hamburg Eppendorf, Hamburg, Germany
[8] ICH Study Ctr, Hamburg, Germany
[9] GSK, Munich, Germany
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
81003
引用
收藏
页码：28 / 30
页数：3
相关论文
共 39 条
  • [1] Two-year outcomes of dolutegravir (DTG) plus lamivudine (3TC) in ART-naive and pre-treated people living with HIV in Germany: real-world data from the German URBAN cohort
    Beer, D.
    Scherzer, J.
    Noe, S.
    Scholten, S.
    Wyen, C.
    Postel, N.
    Degen, O.
    Sabranski, M.
    Westermayer, B.
    Dymek, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 112 - 113
  • [2] Real-world data from the prospective URBAN cohort study on the use of dolutegravir (DTG) plus lamivudine (3TC) in ART-naive and pre-treated people living with HIV in Germany
    Postel, N.
    Schneeweiss, S.
    Wyen, C.
    Schabaz, F.
    Degen, O.
    Weinberg, G.
    Sabranski, M.
    Ummard-Berger, K.
    Dymek, K.
    Westermayer, B.
    Scherzer, J.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 48 - 49
  • [3] 12-month outcomes of dolutegravir (DTG) plus lamivudine (3TC) in ART-naive and pre-treated people living with HIV in Germany: real-world data from the German URBAN cohort
    Scholten, S.
    Noe, S.
    Wyen, C.
    Beer, D.
    Postel, N.
    Degen, O.
    Pauli, R.
    Hillenbrand, H.
    Westermayer, B.
    Dymek, K. M.
    Scherzer, J.
    HIV MEDICINE, 2021, 22 : 111 - 112
  • [4] Three-year outcomes for Dolutegravir (DTG) plus Lamivudine (3TC) in ARTnaive and pre-treated people living with HIV-1 (PLHIV) in Germany: Real-world data from the German URBAN cohort
    Noe, S.
    Scholten, S.
    Wyen, C.
    Sabranski, M.
    Postel, N.
    Degen, O.
    Beer, D.
    Ummard-Berger, K.
    Westermayer, B.
    Dymek, K. M.
    Scherzer, J.
    HIV MEDICINE, 2023, 24 : 137 - 139
  • [5] Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naive HIV-1-infected adults
    Li, Jin
    Chen, Dabiao
    Wen, Zhiwei
    Du, Yanzhang
    Huang, Zhanlian
    Zhong, Huijun
    Wang, Yanhao
    Yin, Sichun
    MEDICINE, 2022, 101 (42) : E31100
  • [6] Real-world implementation of dolutegravir plus lamivudine in people living with HIV in Southwest China
    Yang, Xiaoyan
    Fu, Yanhua
    Xie, Xiaoxin
    Gan, Lin
    Song, Chunli
    Song, Yebing
    Li, Jun
    Long, Hai
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2022, 20 (11) : 1501 - 1508
  • [7] Real-world use of dolutegravir/lamivudine in treatment-naive people living with HIV during the COVID pandemic
    Pierone, G., Jr.
    Fusco, J.
    Brunet, L.
    Vannappagari, V.
    Sarkar, S.
    Henegar, C.
    van Wyk, J.
    Zolopa, A.
    Fusco, G.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 60 - 60
  • [8] Two-year long-term data on the efficacy and tolerability of dolutegravir-based regimens from the prospective multi-centre TESLA cohort study in ART-naive and pre-treated people living with HIV in Russia
    Basova, Anna
    Minaeva, Stella
    Sizova, Natalia
    Nagimova, Firaya
    Orlova-Morozova, Elena
    Radzikhovskaya, Margarita
    Shevchenko, Valeriy
    Maldonado-Doblado, Andres
    Jones, Bryn
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 103 - 105
  • [9] A real-world observational retrospective cohort study of Canadian people living with HIV switching from nevirapine plus two nucleoside reverse transcriptase inhibitors to dolutegravir/lamivudine
    de Wet, Joseph J.
    Ban, Joann K.
    Verdier, Gustavo
    Ling, Juejing
    Eberg, Maria
    Bunko, Andrean
    McKimm, Michael
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2023, 62 (02)
  • [10] DOLAVI study: real-world data (RWD) of dolutegravir plus lamivudine in naive HIV-1-infected patients (week 24)
    Hidalgo-Tenorio, C.
    Pasquau, J.
    Vinuesa, D.
    Ferra, S.
    Terron, A.
    SanJoaquin, I.
    Payeras, A.
    Martinez, O.
    Omar-Mohamed-Balgahata, M.
    De la Torre, J.
    Lopez-Lirola, A.
    Palomares, J.
    Blanco, J. R.
    Montero, M.
    Sequera, S.
    Garcia-Vallecillos, C.
    HIV MEDICINE, 2021, 22 : 130 - 131
1234